Research by Lancaster Uni shows potential treatment for Alzheimer’s with diabetes drug

Researchers at Lancaster University have identified a type 2 diabetes drug that has shown potential benefit in the treatment of Alzheimer’s disease. The treatment combined three older diabetes drugs to create a “triple agonist”, that combines GLP-1, GIP and glucagon. The belief being that boosting levels of growth hormones will aid in protecting the brain

Continue Reading

Positive Early-Stage Clinical Data for Biogen Alzheimer’s Drug

Biogen Idec has announced plans to move their investigational Alzheimer’s drug into Phase III trials, after receiving promising early-stage clinical data. Douglas Williams, Biogen Idec’s R&D chief, noted that in the interim analysis of their Phase Ib clinical trial, aducanumab (also known as BIIB037) showed a significant reduction in the beta-amyloid protein in early-stage patients.

Continue Reading

World’s Largest Dementia Study Launched in the UK

The Medical Research Council (MRC) has announced the launch of the world’s largest study into dementia, involving more than two million people.  The clinical study will be conducted through the Medical Research Council and industry partners. The UK Dementias Research Platform (UKDP) will investigate the causes of dementia across a range of different neurodegenerative conditions,

Continue Reading